Reynald Castaneda

ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.

Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.

Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.

Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.

Deputy Editor Celldex said on Tuesday it will stop investigating its mast cell-targeting monoclonal antibody in a type of chronic itch disease after it failed on all …

Deputy Editor Ipsen has its eyes trained on more M&A — and has €2 billion worth of “firepower” to do it, based on its cash position at the …

The treatment has been linked to seven deaths, largely due to heart or respiratory problems. It has also been associated with over 100 serious adverse events in Prader-Willi patients, raising safety and sales concerns.

Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3 milestone outside of lung cancer.

Akeso CEO Michelle Xia on ivonescimab's biliary tract cancer OS win, ESMO plans and defending HARMONi-6's 0.72 PFS hazard ratio.

Deputy Editor Inhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer …